- Home
- SFST vs BDSX Comparison
SFST vs BDSX Comparison
Compare SFST & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFST
- BDSX
- Stock Information
- Founded
- SFST 1999
- BDSX 2005
- Country
- SFST United States
- BDSX United States
- Employees
- SFST N/A
- BDSX N/A
- Industry
- SFST Major Banks
- BDSX Precision Instruments
- Sector
- SFST Finance
- BDSX Health Care
- Exchange
- SFST Nasdaq
- BDSX Nasdaq
- Market Cap
- SFST N/A
- BDSX 245.3M
- IPO Year
- SFST 1999
- BDSX 2020
- Fundamental
- Price
- SFST $35.38
- BDSX $1.69
- Analyst Decision
- SFST Buy
- BDSX Strong Buy
- Analyst Count
- SFST 1
- BDSX 4
- Target Price
- SFST $44.00
- BDSX $3.08
- AVG Volume (30 Days)
- SFST 19.3K
- BDSX 246.0K
- Earning Date
- SFST 10-21-2024
- BDSX 11-05-2024
- Dividend Yield
- SFST N/A
- BDSX N/A
- EPS Growth
- SFST N/A
- BDSX N/A
- EPS
- SFST 1.70
- BDSX N/A
- Revenue
- SFST $88,995,000.00
- BDSX $60,902,000.00
- Revenue This Year
- SFST N/A
- BDSX $48.06
- Revenue Next Year
- SFST $13.55
- BDSX $29.97
- P/E Ratio
- SFST $20.10
- BDSX N/A
- Revenue Growth
- SFST N/A
- BDSX 46.25
- 52 Week Low
- SFST $24.98
- BDSX $1.15
- 52 Week High
- SFST $39.36
- BDSX $2.21
- Technical
- Relative Strength Index (RSI)
- SFST 69.23
- BDSX 46.06
- Support Level
- SFST $33.88
- BDSX $1.62
- Resistance Level
- SFST $34.61
- BDSX $1.71
- Average True Range (ATR)
- SFST 0.65
- BDSX 0.06
- MACD
- SFST 0.10
- BDSX -0.00
- Stochastic Oscillator
- SFST 96.44
- BDSX 47.62
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.